With a market cap of $143.3 billion, Danaher Corporation (DHR) is a leading global life sciences and diagnostics innovator that combines advanced science, technology, and industry-leading businesses to help customers address complex scientific and clinical challenges and accelerate innovations from discovery to delivery. With approximately 60,000 associates worldwide, the company leverages its Danaher Business System and operational excellence to enable faster, more accurate diagnoses and support the development and delivery of life-changing therapies.
Shares of the industrial and medical device maker have underperformed the broader market over the past 52 weeks. DHR stock has dropped 2.5% over this time frame, while the broader S&P 500 Index ($SPX) has rallied 20.6%. Moreover, shares of the company are down 10.9% on a YTD basis, compared to SPX's 13.9% gain.
